Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
LNK/SH2B3 regulates IL-7 receptor signaling in normal and malignant B-progenitors
Ying Cheng, Kudakwashe Chikwava, Chao Wu, Haibing Zhang, Anchit Bhagat, Dehua Pei, John K. Choi, Wei Tong
Ying Cheng, Kudakwashe Chikwava, Chao Wu, Haibing Zhang, Anchit Bhagat, Dehua Pei, John K. Choi, Wei Tong
View: Text | PDF
Research Article Oncology

LNK/SH2B3 regulates IL-7 receptor signaling in normal and malignant B-progenitors

  • Text
  • PDF
Abstract

Philadelphia chromosome–like acute lymphoblastic leukemia (Ph-like ALL) is a high-risk ALL commonly associated with alterations that affect the tyrosine kinase pathway, tumor suppressors, and lymphoid transcription factors. Loss-of-function mutations in the gene-encoding adaptor protein LNK (also known as SH2B3) are found in Ph-like ALLs; however, it is not clear how LNK regulates normal B cell development or promotes leukemogenesis. Here, we have shown that combined loss of Lnk and tumor suppressors Tp53 or Ink4a/Arf in mice triggers a highly aggressive and transplantable precursor B-ALL. Tp53–/–Lnk–/– B-ALLs displayed similar gene expression profiles to human Ph-like B-ALLs, supporting use of this model for preclinical and molecular studies. Preleukemic Tp53–/–Lnk–/– pro-B progenitors were hypersensitive to IL-7, exhibited marked self-renewal in vitro and in vivo, and were able to initiate B-ALL in transplant recipients. Mechanistically, we demonstrated that LNK regulates pro-B progenitor homeostasis by attenuating IL-7–stimuated JAK/STAT5 signaling via a direct interaction with phosphorylated JAK3. Moreover, JAK inhibitors were effective in prolonging survival of mice transplanted with Lnk–/–Tp53–/– leukemia. Additionally, synergistic administration of PI3K/mTOR and JAK inhibitors further abrogated leukemia development. Hence, our results suggest that LNK suppresses IL-7R/JAK/STAT signaling to restrict pro-/pre-B progenitor expansion and leukemia development, providing a pathogenic mechanism and a potential therapeutic approach for B-ALLs with LNK mutations.

Authors

Ying Cheng, Kudakwashe Chikwava, Chao Wu, Haibing Zhang, Anchit Bhagat, Dehua Pei, John K. Choi, Wei Tong

×

Figure 7

Lnk deficiency enhances IL-7–induced STAT5 activation.

Options: View larger image (or click on image) Download as PowerPoint

Lnk deficiency enhances IL-7–induced STAT5 activation.
(A) Representati...
(A) Representative flow plots of healthy preleukemic and leukemic p53–/–Lnk–/– BM cells stained with of anti-B220 and intracellular IgM (μ–heavy chain, ICμ) antibodies after fixation. (B) Combined B220 and intracellular ICμ staining divide B cells into subpopulations at differentiation stages, which correlate with distinct IL-7 responsiveness. BM cells were starved, stimulated with or without IL-7, and subsequently fixed and stained as described in A, along with anti-pSTAT5 antibodies. Representative histograms of pSTAT5 signal for each population are shown. Dotted vertical lines indicate IL-7 control levels. Percentages of cells responded to IL-7 are indicated. P values are calculated from 2-tailed Student’s t test when compared with WT cells stimulated by IL-7. (C and D) The dot plots show the percentages of pSTAT5+ cells (C) and the MFI of pSTAT5+ signals (D). (E) Lnk–/–p53–/– leukemic blasts show elevated basal activation of pSTAT5. Representative phosphoflow shows the activation status of basal-level pSTAT5 in BM B220loICμ– cells in comparison with leukemic cells after 1 hour of starvation. The dot plots show the quantification of relative MFI of phosphoflow signals. *P < 0.05; ***P < 0.001; ns, not significant, 2-tailed Students’ t test. n = 4–10 mice per group in all above experiments. (F) Lnk–/–p53–/– leukemic blasts were starved and stimulated with or without IL-7 for 20 minuets. Cell lysates were subjected to WB analysis with indicated antibodies to phospho- or total JAKs. (G) HEK293T cells were transfected with mock or JAK3, along with either human or mouse Flag-tagged LNK expression constructs. Cell lysates were either precipitated with anti-Flag antibodies or directly and subjected to WB analysis with indicated antibodies. (H) BaF3/IL-7R cells were stably infected with retroviruses expressing either vector alone, or WT or R384E LNK mutant. Cell growth in the presence of IL-7 was quantified daily and graphed.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts